Pfiz­er strikes an R&D part­ner­ship with Flag­ship's Pro­Found as it looks for next-gen obe­si­ty as­sets

Pfiz­er is open­ing up an­oth­er road to the obe­si­ty mar­ket, an­nounc­ing a part­ner­ship with one of Flag­ship Pi­o­neer­ing’s star­tups to iden­ti­fy new mol­e­cules and tar­gets …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER